SuperworthIntegra Lifesciences free cash flow IART
Cash from operations less capital spending, by quarter and over the last twelve months, from 2009.
- Last 12 months, to Sep 30, 2026
- $85.8M
- Latest quarter, Q3 FY26
- $85.7M
- +233% on a year earlier
- Fiscal year 2025
- −$31.1M
- −224% on the year before
Integra Lifesciences' free cash flow was $85.8M over the twelve months to Sep 30, 2026.
In its latest quarter, Q3 FY26, it was $85.7M, up 233% on the same quarter a year before.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2025 | −$31.1M | −224% |
| FY2024 | $25M | −66% |
| FY2023 | $73.1M | −67% |
| FY2022 | $222.1M | −16% |
| FY2021 | $264.4M | +60% |
| FY2020 | $164.9M | +2% |
| FY2019 | $161.9M | +33% |
| FY2018 | $121.9M | +72% |
| FY2017 | $71M | +3% |
| FY2016 | $69.1M | +12% |
| FY2015 | $61.6M | +59% |
| FY2014 | $38.8M | +616% |
| FY2013 | $5.4M | n/a |
| FY2012 | −$10.3M | −116% |
| FY2011 | $65.9M | −4% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | $85.7M | +233% | $85.8M | |
| Q2 FY26 | $10.5M | n/a | $25.8M | |
| Q1 FY26 | −$5M | n/a | $4.1M | |
| Q4 FY25 | −$5.4M | −126% | −$31.1M | |
| Q3 FY25 | $25.8M | n/a | −$4.5M | |
| Q2 FY25 | −$11.2M | −205% | −$37.4M | |
| Q1 FY25 | −$40.2M | −13907% | −$15.5M | |
| Q4 FY24 | $21.1M | −38% | $25M | |
| Q3 FY24 | −$7.2M | −152% | $38M | |
| Q2 FY24 | $10.7M | −16% | $58.9M | |
| Q1 FY24 | $291K | −98% | $60.9M | |
| Q4 FY23 | $34.2M | −52% | $73.1M |
Against its peers
Companies in Medical - Instruments & Supplies nearest Integra Lifesciences' size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| IARTIntegra Lifesciences | 2.8% |
| IRMDIradimed | 2.3% |
| STAAStaar Surgical | −0.6% |
| MOVMovado | 10.2% |
| BVSBioventus | 7.5% |
| CDRECadre | 6.1% |
| EYENational Vision | 3.3% |
| MDXGMimedx | n/m |
| TCMDTactile Systems Technology | 5.0% |
| LMATLemaitre Vascular | 3.8% |
| INSPInspire Medical Systems | 5.7% |
| Peer median | 5.0% |
Where Integra Lifesciences ranks
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Integra Lifesciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.